Enzistal-P 20 pcs.

1 enteric-coated tablet contains:

active substance:

pancreatin 116.17 mg

Enzistal-P is an enzyme agent.

It contains pancreatic enzymes - amylase, lipase and proteases, which facilitate the digestion of carbohydrates, fats and proteins, which contributes to their more complete absorption in the small intestine.

In diseases of the pancreas, it compensates for the insufficiency of its exocrine function and helps to improve the digestion process.

• Lack of exocrine pancreatic function (including with chronic pancreatitis, cystic fibrosis).
• Chronic inflammatory and dystrophic diseases of the stomach, intestines, liver, gall bladder; conditions after resection or irradiation of these organs, accompanied by disorders of digestion, flatulence, diarrhea (as part of combination therapy).
• To improve the digestion of food in patients with normal gastrointestinal function in case of errors in nutrition, as well as violations of chewing function, forced prolonged immobilization, a sedentary lifestyle.
• Preparation for x-ray and ultrasound examination of the abdominal organs.

The safety of pancreatin during pregnancy is not well understood. Use is possible in cases where the expected benefit to the mother outweighs the potential risk to the fetus.

In experimental studies, it was found that pancreatin does not have a teratogenic effect.

Use in children

Application is possible according to the dosage regimen. With a high activity of the lipase contained in pancreatin, the likelihood of developing constipation in children increases.

Acute pancreatitis, hypersensitivity to pancreatin.

When used in medium therapeutic doses, side effects are observed in less than 1%.

From the digestive system: in some cases - diarrhea, constipation, discomfort in the stomach, nausea. A causal relationship between the development of these reactions and the action of pancreatin has not been established, because these phenomena relate to symptoms of exocrine pancreatic insufficiency.

Allergic reactions: in some cases, skin manifestations.

From the side of metabolism: with prolonged use in high doses, the development of hyperuricosuria is possible, in excessively high doses - an increase in the level of uric acid in the blood plasma.

Other: when using pancreatin in high doses in children, perianal irritation may occur.

With simultaneous use with antacids containing calcium carbonate and / or magnesium hydroxide, a decrease in the effectiveness of pancreatin is possible.

With simultaneous use, it is theoretically possible to reduce the clinical effectiveness of acarbose.

With the simultaneous use of iron preparations, a decrease in iron absorption is possible.

The dose (in terms of lipase) depends on the age and degree of pancreatic function failure. The average dose for adults is 150,000 units / day. With complete insufficiency of exocrine pancreatic function - 400,000 units / day, which corresponds to the daily requirement of an adult for lipase.

The maximum daily dose is 15,000 units / kg.

Children under the age of 1.5 years - 50,000 units / day; older than 1.5 years - 100,000 units / day.

The duration of treatment can vary from a few days (if the digestive process is disturbed due to errors in the diet) to several months or even years (if constant replacement therapy is necessary).

The use of chronic pancreatitis in the acute phase is not recommended.

In cystic fibrosis, the dose should be adequate to the amount of enzymes that is necessary for the absorption of fats, taking into account the quality and quantity of food consumed.

In cystic fibrosis, the use of pancreatin in doses of more than 10,000 units / kg / day (in terms of lipase) is not recommended due to an increased risk of developing strictures (fibrotic colonopathy) in the ileocecal section and in the ascending colon.

With a high activity of the lipase contained in pancreatin, the likelihood of developing constipation in children increases. An increase in the dose of pancreatin in this category of patients should be carried out gradually.

Digestive disorders can occur in patients with hypersensitivity to pancreatin, or in patients with a history of meconium ileus or intestinal resection.

Enteric Coated Tablets